The recent COVID-19 pandemic resulted in the acceleration of the mRNA platform, and the excellent clinical results for safety and efficacy has launched mRNA as a major option for creating new vaccines. However, these vaccines have important limitations, including the ultra-cold chain storage requirements that limits global access., manufacturing cost, and limited duration of immune responses. There is a broad need to increase the accessibility and reduce the cost of manufacturing of mRNA-based vaccines.
VaxForm proposes to incorporate our formulation platform utilizing aluminum adjuvant particles to improve mRNA vaccines’ efficacy and stability. Preliminary data showed that the adjuvant can enhance mRNA protein expression up to two-fold by in vitro assays and stabilized the vaccine for 2 months at 4°C vs the non-adjuvanted vaccine that degraded to 30% efficacy.
Project is utilizing a formulation platform with aluminum adjuvant particles to improve mRNA vaccine's efficacy and stability.
The formulation platform improves efficacy that allows for a reduction of the dose needed to be administered (dose sparing) and therefore reduces manufacturing costs of mRNA vaccines.
The adjuvant allows for refrigerated temperatures for storage thereby facilitating global access by removing ultra cold chain requirements and hence significant cost saving.
Project had the possibility of multivalent mRNA vaccines by combining multiple targets with aluminum adjuvants and reduction of systemic side effects, increasing patience compliance, vaccine coverage and overall global health
By incorporating an established aluminum adjuvant into mRNA vaccine formulations, an organization can reduce manufacturing and cold-chain costs by up to 50%, minimize waste through extended shelf life, and streamline global distribution using standard refrigerated logistics. Regulatory approvals will accelerate due to the adjuvant’s proven safety profile, enabling faster scale-up and commercial readiness without complex process changes. Enhanced stability ensures consistent potency and quality, while improved tolerability and simplified dosing support better patient compliance.
Vaxform aims to demonstrate the dose-sparing and stabilizing effect of aluminum adjuvant onto a mRNA LNP COVID-19 vaccine in vivo with two separate animal studies.
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
VaxForm LLC
